# A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain

> **NCT02081690** · PHASE3 · TERMINATED · sponsor: **Actelion** · enrollment: 160 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Macitentan

## Key facts

- **NCT ID:** NCT02081690
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03-01
- **Primary completion:** 2015-10-01
- **Final completion:** 2015-11-01
- **Target enrollment:** 160 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02081690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02081690, "A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02081690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*